{"id":"tp-44340","type":"article-newspaper","title":"Stoke Therapeutics Expects Q3 2027 EMPEROR Readout and NDA Filing","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/44340","datePublished":"2026-10-30T06:28:47.000Z","dateModified":"2026-10-30T06:28:47.000Z","language":"en","abstract":"About 110 of 162 enrolled patients had completed a week 28 visit. Stoke ended September with $358.8 million in cash and expects available funds, Biogen reimbursements and a potential milestone payment to support opera…","section":"Business","references":[]}